Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NYSE:RDY) on Tuesday reported the re-launch of its US Food and Drug Administration (USFDA) approved over-the-counter (OTC) Famotidine Tablets USP in 10 mg and 20 mg in the US antacids market.
The company's OTC Famotidine Tablets USP in 10 mg and 20 mg is the store-brand equivalent of Johnson & Johnson's Original Strength and Maximum Strength Pepcid AC. This launch will fulfil an important therapy in Antacids market due to Ranitidine withdrawal. The OTC Famotidine Tablets USP, 10 mg and 20 mg, are available in multiple pack sizes to allow consumers a variety of purchasing options.
According to the company, the OTC Famotidine Tablets USP in 10 mg and 20 mg are acid reducers that prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.
For the most recent 12 months ending in August 2020, the Pepcid AC brand and generic had US sales of about USD211m, according to IRi.
Agarwal Joins Dr. Reddy's Laboratories as Chief Financial Officer
Nexus Pharmaceuticals wins FDA approval for Succinylcholine Chloride Injection, USP
Italy's regulatory body clears trial of osteoporosis drug to treat COVID-19
Dr. Reddy's re-distributes OTC Famotidine Tablets USP in 10 mg and 20 mg in the US antacid market
Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis
Antiviral drug remdesivir rationed in Britain as COVID-19 hospitalisations increase
Teva Launches First Generic Versions of HIV-1 Treatments Truvada and Atripla Tablets in the US